Metrika članka

  • citati u SCindeksu: [1]
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:21
  • preuzimanja u poslednjih 30 dana:18
članak: 1 od 1  
Racionalna terapija
2013, vol. 5, br. 2, str. 15-26
jezik rada: srpski, engleski
vrsta rada: izvorni naučni članak
doi:10.5937/racter5-3323


Antimikrobna osetljivost bakterija roda Acinetobakter izolovanih iz inficiranih rana u tercijarnoj zdravstvenoj ustanovi
aKlinički centar Kragujevac, Centar za onkologiju, Kragujevac
bKlinički centar Kragujevac, Služba za kliničku farmakologiju, Kragujevac
cDom zdravlja 'Miloje Hadžić-Šule' Rača Kragujevačka

e-adresa: drivanarosic@gmail.com

Sažetak

Bakterije roda Acinetobakter, a posebno vrsta Acinetobacter baumanii, su jedan od najznačajnijih uzročnika infekcije kod imunokompromitovanih pacijenata u bolničkim uslovima. Cilj istraživanja je bio da se utvrdi na koje antibiotike bakterije roda Acinetobakter, izolovane u brisevima inficiranihrana pacijenata Kliničkog centra Kragujevac pokazuju najveću osetljivost, kao i da se ustanovi da li postoji razlika između in vitro osetljivosti u jedinicama intenzivnog lečenja i drugim, hirurškim i internističkim, odeljenjima. Retrospektivno je analizirano 220 briseva rana pacijenata Kliničkog centra tokom 2011. godine, u kojima je izolovana samo bakterija roda Acinetobakter, i praćena je njena osetljivost na karakterističnu paletu antibiotika. Najveću efikasnost in vitro protiv izolata acinetobaktera u svim analiziranim organizacionim jedinicama Kliničkog centra su pokazali ampicilin sa sulbaktamom, kolistin i tigeciklin. Lekovi na koje su samo poneki izolati Acinetobaktera osetljivi su kotrimoksazol, amikacin, imipenem i meropenem. Acinetobakter pokazuje najveću osetljivost in vitro na ampicilin sa sulbaktamom, kolistin i tigeciklin. Osetljivost izolata Acinetobaktera na antibiotike je manje izražena u jedinicama intenzivnog lečenja u odnosu na druga odeljenja.

Ključne reči

Acinetobacter species; infekcija rane; rezistencija; izbor antibiotika

Reference

Akers, K.S., Chaney, C., Barsoumian, A., Beckius, M., Zera, W., Yu, X., Guymon, C., Keen, E.F., Robinson, B.J., Mende, K., Murray, C.K. (2010) Aminoglycoside resistance and susceptibility testing errors in Acinetobacter baumannii-calcoaceticus complex. Journal of clinical microbiology, 48(4): 1132-8
Bishburg, E., Bishburg, K. (2009) Minocycline--an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii. International journal of antimicrobial agents, 34(5): 395-401
Corbella, X., Pujol, M., Ayats, J., Sendra, M., Ardanuy, C., Domínguez, M.A., Liñares, J., Ariza, J., Gudiol, F. (1996) Relevance of digestive tract colonization in the epidemiology of nosocomial infections due to multiresistant Acinetobacter baumannii. Clinical infectious diseases, 23(2): 329-34
Ecker, J.A., Massire, C., Hall, T.A., Ranken, R., Pennella, T.D., Agasino, I.C., Blyn, L.B., Hofstadler, S.A., Endy, T.P., Scott, P.T., Lindler, L., Hamilton, T., Gaddy, C., Snow, K., Pe, M. (2006) Identification of Acinetobacter species and genotyping of Acinetobacter baumannii by multilocus PCR and mass spectrometry. Journal of clinical microbiology, 44(8): 2921-32
Falagas, M.E., Rafailidis, P.I. (2007) Attributable mortality of Acinetobacter baumannii: no longer a controversial issue. Critical care (London, England), 11(3): 134
Falagas, M.E., Kasiakou, S.K. (2005) Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clinical infectious diseases, 40(9): 1333-41
Falagas, M., Bliziotis, I., Siempos, I. (2006) Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. Crit Care, 10(2): R48-R48
Fass, R.J., Barnishan, J., Solomon, M.C., Ayers, L.W. (1996) In vitro activities of quinolones, beta-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli. Antimicrobial agents and chemotherapy, 40(6): 1412-8
Garrison, M.W., Mutters, R., Dowzicky, M.J. (2009) In vitro activity of tigecycline and comparator agents against a global collection of gram-negative and gram-positive organisms: tigecycline evaluation and surveillance trial 2004 to 2007. Diagn Microbiol Infect Dis, 65(3): 288-299
Gounden, R., Bamford, C., van Zyl-Smit, R., Cohen, K., Maartens, G. (2009) Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections. BMC infectious diseases, 9: 26
Jang, T., Lee, S., Huang, C., Lee, C., Chen, W. (2009) Risk factors and impact of nosocomial Acinetobacter baumannii bloodstream infections in the adult intensive care unit: a case-control study. Journal of hospital infection, 73(2): 143-50
Lee, K., Lee, W.G., Uh, Y., Ha, G.Y., Cho, J., Chong, Y. (2003) VIM- and IMP-type metallo-beta-lactamase-producing Pseudomonas spp. and Acinetobacter spp. in Korean hospitals. Emerging infectious diseases, 9(7): 868-71
Lortholary, O., Fagon, J.Y., Hoi, A.B., Slama, M.A., Pierre, J., Giral, P., Rosenzweig, R., Gutmann, L., Safar, M., Acar, J. (1995) Nosocomial Acquisition of Multiresistant Acinetobacter baumannii: Risk Factors and Prognosis. Clinical Infectious Diseases, 20(4): 790-796
Mahgoub, S., Ahmed, J., Glatt, A.E. (2002) Underlying characteristics of patients harboring highly resistant Acinetobacter baumannii. American journal of infection control, 30(7): 386-90
Maragakis, L.L., Perl, T.M. (2008) Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clinical infectious diseases, 46(8): 1254-63
Mioljević, V., Jovanović, B., Mazić, N., Palibrk, I., Milićević, M. (2009) Rezultati epidemiološkog nadzora nad bolničkim infekcijama na Klinici za digestivnu hirurgiju KCS u 2007. godini. Acta chirurgica iugoslavica, vol. 56, br. 2, str. 47-51
Mioljević, V., Simić, A.P., Radenković, D., Galun, D., Palibrk, I., Ostojić, S., Stojakov, D., Varagić, Z., Pavlović, M., Milićević, M.N. (2011) Acinetobacter spp. - faktori rizika za kolonizaciju i infekciju kod hirurških bolesnika. Acta chirurgica iugoslavica, vol. 58, br. 4, str. 81-87
Peleg, A.Y., Seifert, H., Paterson, D.L. (2008) Acinetobacter baumannii: emergence of a successful pathogen. Clinical microbiology reviews, 21(3): 538-82
Poulakou, G., Kontopidou, F.V., Paramythiotou, E., Kompoti, M., Katsiari, M., Mainas, E., Nicolaou, C., Yphantis, D., Antoniadou, A., Trikka-Graphakos, E., Roussou, Z., Clouva, P. (2009) Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens. Journal of infection, 58(4): 273-84
Rhomberg, P.R., Jones, R.N. (1999-2008) Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States. Diagn Microbiol Infect Dis, 65(2009): 414-426
Sinha, M., Srinivasa, H., Macaden, R. (2007) Antibiotic resistance profile & extended spectrum beta-lactamase (ESBL) production in Acinetobacter species. Indian journal of medical research, 126(1): 63-7